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Gender dysphoria describes the psychological distress
caused by identifying with the sex opposite to the one
assigned at birth. In recent years, much progress has been
made in characterizing the needs of transgender persons
wishing to transition to their preferredgender, thushelping to
optimize care. This critical review of the literature examines
their common mental health issues, several individual risk
factors for psychiatric comorbidity, and current research on
the underlying neurobiology. Prevalence rates of persons
identifying as transgender and seeking help with transition
have been rising steeply since 2000 across Western countries;
the current U.S. estimate is 0.6%. Anxiety and depression are
frequently observed both before and after transition,
although there is some decrease afterward. Recent research
has identiﬁed autistic traits in some transgender persons.
Forty percentof transgender personsendorse suicidality, and
the rate of self-injurious behavior and suicide are markedly
higher than in the general population. Individual factors
contributing tomental health in transgender persons include
community attitudes, societal acceptance, andposttransition
physical attractiveness.Neurobiologically,whereas structural
MRI data are thus far inconsistent, functional MRI evidence in
trans persons suggests changes in some brain areas con-
cerned with olfaction and voice perception consistent with
sexual identiﬁcation, but here too, a deﬁnitive picture has yet
to emerge. Mental health clinicians, together with other
health specialists, have an increasing role in the assessment
and treatmentofgenderdysphoria in transgender individuals.
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Identifying with the sex opposite to the one assigned at birth
oftenevokes serious distress anddysphoria,whichare likely to
be exacerbated by the legal, social, vocational, family, and
relationship consequences of such an identiﬁcation, including
social stigma. Moreover, such distress can lead to a variety of
mental health problems. As a result, many individuals expe-
riencing genderdysphoria search forgender-transition-related
care (1). Our aim in this selective review is to provide an
overview of current research in transgender persons, focusing
on mental health and mental health problems and their neu-
robiological and neurocognitive and affective underpinnings.
Currently, to facilitate transition, lines of care include cross-sex
hormone treatment (CSHT) and/or gender-afﬁrming surgery.
The beneﬁcial effects of these lines of care on mental health
and neurobiology will be scrutinized here.
Transgender care is complex and highly interdisciplinary.
It involves a variety of health professionals, including en-
docrinologists, gynecologists, urologists, surgeons, voice and
communication specialists and therapists, dermatologists,
and various providers of mental health services (psychia-
trists, clinical psychologists, counselors, etc.) (2). In linewith
the goals of the World Professional Association for Trans-
gender Health (2) to de-psychopathologize being trans-
gender, the terminology has been constantly evolving in
recent years. For persons identifyingwith the sex opposite to
the one assigned at birth, we use the currently preferred
terms “trans persons” or “transgender persons” throughout
this review. The term “transgender men” is used for persons
transitioning from female to male and “transgender women”
for persons transitioning frommale to female. In most cases,
but not all, we refer to personswith gender dysphoria visiting
mental health services and seeking gender-afﬁrming surgery.
Whereas some individuals may not be distressed by expe-
riencing incongruence between their gender identity and
their sex assigned at birth, a formal DSM-5 diagnosis of
gender dysphoria is still necessary in many countries to fa-
cilitate access to mental health care and other professional
care thatwill help in the transition to the experienced gender.
The term “cisgender persons” is used throughout the review
to describe persons who did not transition and who identify
with their sex assigned at birth, for example, a female
identifying as female and with female sex assigned at birth.
EPIDEMIOLOGY
Epidemiologically, true prevalence rates of transgenderism
are difﬁcult to establish because of sampling biases (2).
Concerns in establishing prevalence rates start with the
criteria for inclusion, that is, whether the person has already
undergone gender-afﬁrming surgery, is receiving CSHT, or
has presented with gender dysphoria to a mental health
provider. Because of this bias, estimated prevalence rates
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have traditionally been underestimates, as some gender-
variant individuals (i.e., associating oneself with a sex differ-
ent from the one assigned at birth without being dysphoric)
may never present to a mental health care provider. To
overcome these limitations, recently published prevalence
estimates are conducted using meta-analytic methods or
population-based surveys. Using ameta-analysis on reported
prevalence rates, Arcelus et al. (3) estimate the prevalence of
persons being transgender at around 4.6 per 100,000, with
6.8 for transgender women and 2.6 for transgender men.
Exploiting nationally available population surveys in the
United States, Flores et al. (4) suggest a total prevalence of 0.6%
for adults in the U.S. population identifying as transgender
persons. The prevalence of gender dysphoria has been in-
creasingworldwide in the past two decades. Potential reasons
could be that concerned persons feel freer to disclose their
dysphoria and to seek help because of more openness in so-
ciety, changes in legislation, and a trans-afﬁrmative approach
on the part of mental health and medical care providers, the
media, and social media. However, other changes in inter- or
intraindividual factors are also plausible.
Ofnote, genetic issues in the synthesis of steroidhormones
do not appear to contribute to the prevalence of gender
dysphoria. Individuals with disorders of sexual development,
such as congenital adrenal hyperplasia, complete or partial
androgen insensitivity syndrome, or other, more rare variants
of disorders of sexual development, do notmeet the diagnostic
thresholds for gender dysphoria (5, 6). Rather, it has been
reported thatwomenwith congenital adrenalhyperplasiamay
be more likely to have a non-heterosexual orientation (7, 8).
MENTAL HEALTH IN TRANSGENDER PERSONS
Much cross-sectional work on mental health in transgender
persons has focused on documenting the psychological or
psychiatric problems thatmayaffect a transgender person. In
a large initiative across four European countries, Heylens
et al. (9) reported that 38% of transgender persons with
gender identity disorder (N=305) currently had axis I di-
agnoses, the majority of which were affective (27%) and
anxiety disorders (17%). Notably, lifetime prevalences of axis
I diagnosis, affective problems, and anxietywere estimated at
70%,60%, and28%, respectively,while axis IIdiagnoseswere
estimated at 15%. Substance use disorders, eating disorders,
and psychotic disorders were less prevalent, at 16%, 2%, 1%,
respectively. The problematic high rates of psychological
and/or psychiatric problems in trans persons remained even
when participants were matched with cisgender compari-
son subjects and additional factors such as age, natal sex, and
new assigned sex were taken into account in a retrospective
Swedish cohort study (10). While such high rates of psy-
chopathology are consistently reported in the literature,
there is disagreement regarding sex speciﬁcity. Whereas
some studies document higher prevalences of psychopa-
thology in transgender women relative to transgender men
(11–13), one study reported the reverse (14).
Interestingly, in addition to the axis I disordersmentioned
above, attention in the ﬁeld has recently shifted to the presence
of autism spectrum disorders or autistic traits in transgen-
der persons. While any conclusions would still be premature,
currently available data appear to suggest higher rates of co-
occurringautistic traits intranspersonswithgenderdysphoria
relative to the general population in Dutch children (N=204)
(15) and British adults (16). In the latter study (16), trans men
(N=61)butnot transwomen(N=198)hadhigherautismquotient
scores than cisgender men and women but lower scores than
125patientswithadiagnosisofAsperger’ssyndrome.Thesedata
suggest that while autistic traits in trans personsmay be higher
than in the general population, they may be lower than in the
populationof peopleon the autismspectrumandaredependent
on sexual orientation or sex.
Despite these concerning rates of psychopathology and
axis I and II disorders, emergent longitudinal research has
begun to document the positive change in mental health
associated with successful transition. This research shows
signiﬁcant reductions in psychopathology after transition,
down to a level resembling normative data (for a compre-
hensive review, see reference 17). In one longitudinal study of
107 transgender persons (18), symptoms of anxiety, depres-
sion, and psychoticism and measures of global severity and
functional impairment were all signiﬁcantly reduced after
12 months of CSHT. Similarly, another study (19) also tested the
beneﬁcial effects of CSHT on mental health in both a cross-
sectional and longitudinal design. Cross-sectionally, the study
found that CSHT alleviated depressive symptoms in trans men
but not trans women relative to trans persons not receiving
hormones. With hormone therapy, levels of body uneasiness in
both genders also diminished. Crucially, longitudinally across
four time points (at 3, 6, 12, and 24 months of follow-up), CSHT
was associated with signiﬁcant reductions in psychopathology
(on theSymptomChecklist–90 global severity index), depressive
symptoms, body uneasiness levels, and gender dysphoria in both
genders (19). In sum, while being trans may be associated with
increased mental health problems, predominantly affective dis-
orders, promisingﬁndings are emerging that indicate a reduction
of mental health–related psychopathology, including depression
and body dissatisfaction, with time and hormonal treatment.
Nonetheless, amajor concern in transpersons remains the
risk of suicidality (suicidal thoughts, suicide attempts, and
suicide rates) as well as nonsuicidal self-injury, such as
cutting, hitting, or burning oneself. These behaviors may
reﬂect a maladaptive way to regulate one’s emotion, or self-
punishment in response to external or internal pressure and
social stigma. Because of these high-risk behaviors, the past
decade has seen a surge in studies assessing the presence of
suicidality and nonsuicidal self-injury in trans persons, with
steadily increasing sample sizes. Rates of lifetime suicidality
and suicide attempts for trans persons are alarming, ranging
from 30% to 81% (the prevalence rate of suicide attempts in
the overall U.S. population is estimated at 4.6%) (9, 20–22).
Signiﬁcant predictors of suicide include a past history of
maltreatment, gender victimization, depression, substance
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abuse, and young age (20–22). Rates for lifetime nonsuicidal
self-injury in the pretransition period are estimated at 38%
for the total trans population, with 57.7% in trans men and
26.2% in trans women (11). Although another study reported
much lower rates of nonsuicidal self-injury (19%) (23), both
studies found that trans men were more at risk of nonsuicidal
self-injury than trans women. These results are shared by in-
vestigations inpediatricpopulations,whichalsoreportelevated
rates of self-harm in children and adolescents with gender
dysphoria (24), suggesting that suicidality and self-injurious
behavior are prominent across the lifespan in this population.
Long-term data assessing suicidality and nonsuicidal self-
injury after transition are fewer but continue to signal cause
for concern. Retrospective data on 1,331 trans persons who
visited a university gender clinic (25),with amedian follow-up
of 18.5 years, indicated high mortality rates among trans
women, with a total mortality 51% above the general pop-
ulation average (rates of total and cause-speciﬁc mortality
among transmen did not differ signiﬁcantly from those of the
general population). Causes of death included heart and lung
problems, neoplasm,HIV/AIDS, andsuicide (17 transwomen
relative to one trans man). Death by suicide and suicide at-
tempts after transition were equally alarming in the Swedish
cohort study byDhejne et al. (10), who reported an incidence
of 2.7 per 1,000 person-years for death by suicide and 7.9 for
suicide attempts. Notably, the National Transgender Dis-
crimination Survey uncovered a high prevalence of 41% for
suicide attempts in transpersons—double that reported in the
LGB (lesbian, gay, bisexual) community,which is estimated at
10%220% for the U.S. population (26). Such high rates of
suicide risk in trans persons, even after transition, would
mandate that transpersonspresentingat theclinicnotonlybe
assessed for self-injurious behavior but also be monitored
longitudinally.
Indeed, the recognition of being trans as an identity, rather
than as a mental health disorder (2), is shifting the focus of
the clinician’s preassigned role. Given the high rates of mood
and affective disorders as well as high suicidality in trans
persons, especially before transition, clinicians must be able
to diagnose not only gender dysphoria but also interrelated
psychological and/or psychiatric problems as well as psy-
chological problems that may masquerade as gender dys-
phoria. In addition, it is recommended that mental health
care providers be familiar with the criteria for diagnosis and
treatment of gender dysphoria and be able to care for the
patient during the entire transition process and afterward.
SOCIAL, ENVIRONMENTAL, AND
INDIVIDUAL FACTORS
Social, legal, vocational, and environmental factors contrib-
ute greatly to the well-being of trans persons. Whereas the
level of life satisfaction among 6,771 trans persons in a large
European Union lesbian, gay, bisexual, and transgender
(LGBT) survey (N=93,079) was similar to that of the general
population, it was nonetheless somewhat lower than that of
nontrans respondents from the LGB community (27). This
report also uncovered continuing problems that trans per-
sons face with stigma, harassment, and violence and mal-
treatment in their personal and professional lives. Forty-six
percent of trans persons in the survey reported having felt
discriminated against or harassed within a 12-month period
because of being perceived as trans (27), including 30% of
trans persons when looking for a job and 23% at the work-
place. Such social and environmental factors very likely
contribute to mental health problems and suicidality. In a
sample of U.S. LGBT youth (N=246, ages 16–20) (28), pro-
spective LGBT victimization and low social support were
associated with suicidal ideation, and self-harm was asso-
ciated with (among other factors) childhood gender non-
conformity, prospective hopelessness, and victimization.
Interindividual factors, including sexual orientation and
physical appearance, may also contribute to well-being and
mental health. In an interesting investigation into putative
subtypes within the transgender population, Smith et al. (29)
gathered data from 187 trans persons who had completed
gender-afﬁrming surgery and examined the role of sexual
orientation on personality variables, physical appearance,
onset of gender dysphoria (documented gender identity
disorder), and psychopathology. Participant’s physical ap-
pearance (facial hair, height, ﬁgure, nose, muscularity,
speech, etc.) was rated in terms of how compatible this ap-
pearance was with the new (preferred) sex. These rat-
ings showed that androphilic trans men compared with
gynephilic trans women had a higher matching physical
appearance. Moreover, androphilic trans women and gyne-
philic trans men, compared with gynephilic trans women
and androphilic trans men, reported more gender identity
disorder symptoms in childhood. Similarly, trans men also
reported more gender identity disorder symptoms at early
ages relative to trans women and applied for transition at
an earlier age. These results may point to different under-
lying factors and motivations. Smith et al. (29) suggest that
whereas androphilic transwomenmayhavea strong aversion
to their sex organs, motivating earlier transition, gynephilic
transwomenmay have grown up asmasculine boys and may
also have entered marriage and fathered children, thus
leading to later transition. Similarly, androphilic trans men
reported more psychological problems than gynephilic
trans men, suggesting that a combination of sexual attraction
to a speciﬁc gender, physical appearance, and societal expec-
tations may exert different effects on individuals with differ-
ent sexual orientations or different age at onset of gender
dysphoria (30).
The data are currently ambiguous, however, as an Italian
study (19) found that although subjective gender dysphoria,
depressive symptoms, and psychopathology decreased with
CSHT, the social and socio-legal factors of gender dysphoria
increased, particularly for trans men. These authors argued
for a culturally speciﬁc explanation of this effect but re-
grettably did not explore this option further. However, the
ﬁndings from the European Union survey cited above (27)
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support such conjectures, given substantial differences
among member states in perception of discrimination, social
stigma, and hate-related crime. However, more converging
evidence and research endeavor in this domain are needed
before more deﬁnitive conclusions can be drawn. In addi-
tion to research into these social and environmental factors,
much recent work has examined the underlying neurobiol-
ogy in transgender persons.
STRUCTURAL NEUROANATOMY AND
RESTING-STATE ACTIVITY
Despite intensive searching, no clear neurobiological marker
or “cause” of being transgender has been identiﬁed. Yet
functional MRI (fMRI) and structural MRI studies of the
brain in trans persons have been surging over the past decade
to chart the complex contributions of underlying neurobi-
ology.Hunting for aneurobiological etiology in transpersons,
themajority of studies in this domainhave examinedwhether
the brains of trans persons resemble those of their sex
assigned at birth, resemble those of their gender identity, or
are intermediate to either sex. These structural MRI studies
have predominantly focused on persons pretreatment and
have reported mixed ﬁndings. Various factors contribute to
these mixed results, including the use of different regions of
interest, as well as statistical power issues, with sample sizes
ranging fromsingle case studies to around24participants per
group, with slightly higher samples for cisgender control
groups (31). In some of the largest studies available in hor-
monally untreated transgender persons, gray matter volume
(32, 33) and total brain volume (33) were similar for trans
persons relative to their sex assigned at birth. Findings in
other global measures, such as in the corpus callosum, are
mixed and do not showany difference in size in trans persons
before (34) or after CSHT (35), although they indicate a
corpus callosum shape consistent with their gender identity
(36). As for subcortical structures, putamen volume is
either larger (32) or smaller (33) in trans women relative to
cisgendermen, with other studies suggesting a larger volume
in trans women relative to cisgender women (35). Coming
close to providing a neurostructural correlate of being a trans
person, a valuable histological study in 42 postmortem brains
(37) reported that the size of the hypothalamic uncinate
nucleus (INAH-3) in 10 trans women resembled that in
cisgender women, that is, it was consistent with their gender
identity rather than their sex assigned at birth. Even though
the trans persons in this postmortem study had been hor-
monally treated, the lack of testosterone did not appear to be
the primary causative factor, given the absence of such an
anatomical effect in nontrans castrated men, ﬁve of whom
were also examined in the study. These data highlight the
importance of paying close attention to regionally speciﬁc,
minute structureswhen assessingwhich brain areas conform
to gender identity rather than sex assigned at birth.
In comparison to these studies on graymatter volume, the
few available white matter studies agree on an intermediate
phenotype for trans persons in many sexually dimorphic
fascicles yet disagree on the parameters tested and the
precise order of group ﬁndings. In 3-T diffusion tensor im-
aging studies, Kranz et al. (38) documented widespread
group differences in mean diffusivity between four groups
(hormonally untreated transgender men and women and
cisgender men and women). Cisgender women had the
highest mean diffusivity values, followed by transgender
men, transgender women, and cisgender men. Moreover, no
differences were found in fractional anisotropy. Directly
contrasting these ﬁndings, Rametti et al. documented, in
separate reports on trans men (39) and trans women (40),
differences in fractional anisotropy, with larger values for
cisgender men relative to cisgender women, values for trans
menbeingmore similar to cisgendermen, andvalues for trans
women falling between those of the cisgender groups.
Although markedly fewer longitudinal studies or studies
in trans persons after gender-afﬁrming surgery and/orCSHT
have been published, the few that have are promising. Con-
ﬁrming histological ﬁndings of a female-sized hypothalamus
in trans women (37), Hulshoff Pol et al. (41) documented a
decrease in hypothalamus size in this cohort with CSHT.
Conversely, Kimet al. (42) found an increase in hypothalamic
volume in trans men, suggesting plasticity and sensitivity of
the hypothalamus to CSHT to shift toward the identiﬁed
sex. A treatment study examining cortical thickness after
6 months of CSHT (43) indicated a variety of cortical
thickness increases with androgen treatment in trans men
and decreases with estrogens and antiandrogens in trans
women. Again providing complementary evidence, while
that study reported a volume increase in the global ven-
tricular system in trans women, other groups have docu-
mentedspeciﬁc reductions in thirdventricle size in transmen
with hormonal treatment (35, 41). Some, however, have
suggested that this ﬁnding is related to volumetric changes in
adjacent gray matter structures, including the hypothalamus
(41), a conjecture requiring further conﬁrmation. However,
serious caveats of currently available structural MRI studies
include small numbers of transgender persons and cisgender
comparison subjects (41), an absence of a cisgender com-
parison group (to establish baseline values for cisgendermen
and women) (43), an absence of pretreatment data (35), or
separate publication of trans men and trans women, thus not
allowing direct comparison (39, 40). Moreover, given the
clinical implications of early versus late age at onset of gender
dysphoria and sexual orientation (30), such variables deserve
future scrutiny.
In addition to characterizing gray and white matter dif-
ferences in transgender persons, structural and functional
connectivity studies have also begun to emerge (44, 45). In a
structural connectivity study of transgender persons before
CSHT, Hahn et al. (44) documented decreased structural
hemispheric connectivity ratios for transgender persons
relative to cisgender persons in subcortical brain areas. In an
MRI study examining local resting-state activity, Mueller
et al. (45) recently observed that circulating androgen levels
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in trans men were associated with local resting-state activity
in the frontal cortex and the cerebellum, an effect that was
moreover linked toCSHTduration, at least in the cerebellum.
No such effects of estrogen were found in transgender
women. Taken together, structural MRI studies appear to
show,dependingon thebrain regionqueried, an intermediate
phenotype or a phenotype consistent with gender identity in
trans persons that may shift further toward the experienced
gender with CSHT (with other brain areas being consistent
with sex assigned at birth). Yet, a unique neurobiological
locus of “being transgender” remains to be identiﬁed, and
more corroborative evidence utilizing larger and better-
powered controlled studies is needed before any deﬁnitive
conclusions can be drawn. Joint imaging initiatives to
compensate for these shortcomings are lacking at this stage.
Nonetheless, some of these structural discoveries have led to
important work on the functional implications of these
changes.
FUNCTIONAL NEUROANATOMY
Although currently even more limited than structural im-
aging studies, fMRI studies on neurocognitive or affective
processes have emerged, creating an intriguing line of work
based on earlier anatomical and histologicalﬁndings. Indeed,
exploiting the early discovery of a female-like hypothalamus
(37) and bed nuclei of the stria terminalis (BNST) (46) in
transgenderwomen, researchers recently aimed to probe the
functional implicationsof thisﬁnding.Thehypothalamusand
BNST are centrally connected with other limbic structures
such as the amygdala and the hippocampus and occupy a
central role in hormonal signaling in sex-differentiated be-
havior. Studies set out to assess this impact in olfactory
processing. Males and females are sensitive to estratetraenol
and androstadienone, respectively, both steroid compounds
with pheromone capability in humans and known to activate
the hypothalamus. Berglund et al. (47) discovered that ac-
tivation of the hypothalamic network to olfactory encounter
of androstadienone in trans women was similar to that of
cisgender women and different from that of cisgender men.
Burke et al. (48) replicated this ﬁnding with 3-T fMRI in a
larger sample of either prepubertal or pubertal children and
adolescents with gender dysphoria (36 children and 38 ado-
lescents) and without gender dysphoria (39 children and
41 adolescents). Interestingly, these additional developmental
ﬁndings revealed that the sexually differentiated response of
the hypothalamus was already present when comparing
prepubertal cisgender boys with cisgender girls but that the
difference in youths with gender dysphoria only began to
emerge in adolescence andwas consistent prepubertallywith
sex assigned at birth.
Whereas olfaction is a largely subliminal process, voice
and speech perception are both processed sub- and supra-
liminally and contribute much to the perception of gender.
Therefore, attention in transgender care is also directed
toward the perceived voice and speech before and after
transition. In transgender men, testosterone treatment may
deepen the voice to approach male vocal pitch. However, in
transgenderwomen, estrogens do not have such an effect and
vocal surgery and/or speech therapy may be needed (2).
Indeed, speech therapists, speech-language pathologists, or
speech-voice clinicians may all contribute to helping a
transgender person accomplish the pitch, intonation, speech
rate, or phrasing patterns as well as the nonverbal commu-
nication of their desired sex (2). Related fMRI research has
examined how a male or female voice is perceived in trans
women. Junger et al. (49) examined voice gender perception
of male and female voices in a German sample of hormonally
treated (N=16) and untreated (N=17) trans women in com-
parison to cisgender men (N=21) and women (N=20). These
male or female voices were presented “pure” or were mod-
iﬁed and presented in semitone steps toward one or the other
gender. Whereas cisgender men differed from cisgender
women in their response timeswhen identifying voices of the
opposite sex, reaction timeswere in between for transgender
women. Consistent with such a response pattern, when
voices were morphed toward the other sex, neural activation
in the superior frontal gyrus in transwomenwasmore similar
to that of cisgender women and less similar when compared
to cisgender men.
Other neurocognitive work in transgender persons has
focused on functions commonly hypothesized to show
“typical” sex differences in performance and to assess the
extent to which CSHT would shift performance toward the
gender identity in trans persons. Two such sex-stereotypical
tasks aremental rotation (a spatial cognition task, said to favor
males) and language and verbal ﬂuency tasks (said to favor
females). Starting with the ﬁrst of these, in the largest cross-
sectional study to date on mental rotation abilities in trans
persons, hormonally treated trans women (N=18) exhibited
reduced parietal lobe activation, a region commonly active
during mental rotation, relative to cisgender men but in-
creased activation in the right orbital and dorsolateral pre-
frontal cortex relative to cisgender women (50). By contrast,
no group effects were observed for trans men. Given the
absence of pretreatment data in that study, it is difﬁcult to
assess whether the observed effects resulted from the CSHT
or existed prior to it. Interestingly, a partial answer to this
question is provided by Schöning et al. (51), who documented
increased parietal cortex activation duringmental rotation in
cisgender men relative to both hormonally treated and un-
treated trans women. This would suggest that transgender
women are more similar to their gender identity in their
neural response during mental rotation, an effect that may
occur prior to hormonal treatment.
In tasks hypothesized to favor females, ﬁndings have been
mixed. In a pretreatment sample of adolescents with gender
dysphoria, Soleman et al. (52) reported better behavioral
performance in trans girls in a verbal ﬂuency task (i.e., word
production). Curiously, these trans girls resembled neither
their sex assigned at birth nor their gender identity but
produced more words (phonetic ﬂuency) than any of the
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other three groups. Yet, at the brain level, group differences
revealed a larger activation in cisgender boys relative to
cisgender girls in the Rolandic operculum, and brain activity
in the transgender groups was at levels in between these
groups. In a small study of CSHT (six trans men and eight
trans women), Sommer et al. (53) examined two language-
based tasks (verb generation and categorical decision) and
reported an increase in language activation in both trans-
gender groups after treatment, an effect that was associated
with posttreatment estradiol levels for both sexes. Taken
together, unfortunately, ﬁndings from this line of work ex-
amining sex-typical and sex-atypical neurocognitive differ-
ences are inconclusive because of very small samples (51, 53),
effects that failed to reach statistical signiﬁcance (52), lack of
pretreatment data (50), or non-sex-speciﬁc hormonal effects
(affecting both sexes) (53). While presenting an encouraging
ﬁrst set of preliminary studies to build upon, no conclusions
can yet be drawn as to the effect of CSHT on sex-typical
cognitive performance or the presence of pretreatment
neurocognitive differences. Surprisingly, despite the high
rates of affective disorders in trans persons, no published
research to date has examined the neural correlates of
emotional or affective responding in this population.
LIMITATIONS AND FUTURE PERSPECTIVES
Many studies in transgender persons suffer from methodo-
logical shortcomings, including small or very small sample
sizes, ranging from 10 to 25 trans persons per group (with
some exceptions, e.g., 48). Low statistical power is particu-
larly problematic when the aim is to show the presence of an
intermediate phenotype, whichmaymake it difﬁcult to show
signiﬁcant differences when results for the group of interest
(trans persons) fall in between those of the control groups
(cisgender persons). Thus, better-powered and multicenter
studies are needed. Some initiatives in that direction have
already formed, such as the European Network for the In-
vestigation of Gender Incongruence (ENIGI initiative),
which aims to assess differences in gender dysphoria among
different European countries. Indeed, the ENIGI initiative
revealed that some sociodemographic characteristics, in-
cluding education level, age, and number of persons
(trans men or trans women) presenting to the clinic, may
already differ amongEuropean countries (Norway, Germany,
Belgium, and the Netherlands) (54), suggesting the utility of
including such factors in future work. Indeed, such country-
speciﬁc phenomena may account for some of the differences
reported in the literature, for example, whether psychopa-
thology is higher in transmenor transwomen (9, 12, 14). Even
though such initiatives may need to overcome country-
speciﬁc limitations, including type of CSHT, legal struggles
with acknowledgment of transition status, and recruitment
pool (i.e., only through referral, mental health centers, or
focus and activist groups), they allow sample sizes large
enough to assess critical factors related to mental health and
care, including quality of life and satisfaction before and after
transition. Speciﬁcally, longitudinal research is urgently
needed, given that treatment protocols and available care in
speciﬁc countries have changed dramatically over the past
few years. During such longitudinal work, the effects of
CSHT on psychology during the transition process also re-
quire more attention. Likewise, neurobiological work would
see signiﬁcant improvements in explanatory power during
joint initiatives or pooling of samples.
More comparative work between countries is also needed
to establish optimal procedures, and the effects of CSHT on
the brain and behavior require further conﬁrmation and
validation. Fortunately, the World Professional Association
for Transgender Health has set out clearly deﬁned treatment
standards providing clinical guidance tomeet the health care
needs of trans persons thatmay be adjusted depending on the
cultural context or the individual and that consequently
provide a standardized yet sufﬁciently ﬂexible framework
(Standards of Care for the Health of Transsexual, Trans-
gender, and Gender-Nonconforming People, Version 7) (2).
CONCLUSIONS
Since the beginning of the century, much progress has been
made in charting the mental health needs of transgender
FIGURE 1. Overview of Key Issues and Findings in Current
Transgender Research
Key fi ndings
•  Prevalence of number of people presenting to gender 
clinics is increasing
•  Evidence of biological etiology is still limited
•  Trans persons experience a high rate of aff ective disor-
ders, especially depression and anxiety, as well as a high 
risk of suicidality and nonsuicidal self-injury
•  Recent research trends include preliminary ﬁ ndings of 
elevated autistic traits in trans persons
•  Gender-affi  rming surgery and/or cross-sex hormone 
treatment decrease mental health problems, body uneas-
iness, and gender dysphoria but not necessarily suicidality
•  A high rate of trans persons ﬁ nd discrimination both in 
personal and professional lives
•  Search for neurobiological correlates of transgenderism 
is still ongoing
•  There have been promising functional MRI ﬁ ndings in 
voice perception and olfaction
Key issues
•  Structural MRI research is often discrepant but consis-
tently shows some eff ects
•  Sample sizes are increasing in behavioral research but 
remain small in neurobiological studies
•  Currently there is no neuro-aff ective research in trans 
persons
•  There have been no randomized controlled trials yet on 
cross-sex hormone treatment
•  There is a paucity of data in trans adolescents
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persons alongside essential discoveries of underlying neu-
robiology (33, 37, 38) and associated function (47, 48)
(Figure 1). Available data suggest high rates of affective
disorders (9, 17–19) thatmaydecreasewith treatment (18, 19),
although suicide risk remains a cause for concern (9, 20, 22,
26). The currently increasing efforts to characterize the
changes associated with transition to the preferred sex are
promising (19, 41, 45) but require larger-scaled collaborations
for future validation and conﬁrmation (54). We hope that
such a research agenda will also contribute to a reduction in
social stigmaandanenvironment inwhichall persons receive
optimal care regardless of sex or sexual orientation.
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